Ask AI
PulseCast Nonmalignant Disorders ASH 2025
PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting

Released: December 18, 2025

Activity

Progress
1
Course Completed

In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including:

  • LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment
  • Abstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapy
  • Abstract 5: Deciphering the dilemma: intravenous (IV) iron use in iron deficiency anemia during acute infections
  • Abstract 308: Subcutaneous, every-4-week maintenance dosing of a novel protein S antibody is well tolerated and substantially reduces bleeding rates: results from a phase I/II multidose study of VGA039 in patients with von Willebrand disease
  • Abstract 841: Immune thrombocytopenia in patients treated with immune checkpoint inhibitors